Jeffrey G Hesselberg

20180325858, Nov 15, 2018

Mar 2, 2018

15/910505

- Memphis TN, US
Jeffrey G. Hesselberg - Germantown TN, US
Mary Ann Johnston - Memphis TN, US
Robert H. Getzenberg - Memphis TN, US

GTx, Inc. - Memphis TN

A61K 31/277
A61K 31/00
A61K 31/167

The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence, urge urinary incontinence, mixed incontinence, and pelvic floor disorders by administering a SARM compound of the invention.

20180177755, Jun 28, 2018

Sep 13, 2017

15/702757

- Memphis TX, US
Jeffrey G. Hesselberg - Germantown TN, US
Mary Ann Johnston - Memphis TN, US
Robert H. Getzenberg - Memphis TX, US

GTx, Inc. - Memphis TN

A61K 31/277
A61K 31/00
A61K 31/167

The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic floor disorders by administering a SARM compound of the invention.

20160106702, Apr 21, 2016

Oct 16, 2015

14/885818

- Memphis TN, US
Jeffrey G. Hesselberg - Germantown TN, US
Mary Ann Johnston - Memphis TN, US
Robert H. Getzenberg - Memphis TN, US

A61K 31/277
A61K 31/167

The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence and pelvic-floor disorders by administering a SARM compound of the invention.

20140134274, May 15, 2014

Oct 24, 2013

14/062748

- Knoxville TN, US
Mary Ann Johnston - Memphis TN, US
Michael L. Hancock - Memphis TN, US
Jeffrey G. Hesselberg - Germantown TN, US
James T. Dalton - Lakeland TN, US

University of Tennessee Research Foundation - Knoxville TN

A61K 31/277
A61K 31/555
A61K 31/337
A61K 31/519
A61K 31/4745
A61K 33/24
A61K 31/706

424649, 514522, 514492, 514 49, 5142651, 514283, 514449

This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.